MHC class II alleles in ulcerative colitis-associated colorectal cancer

Gut

Volumn 58, Issue 9, 2009, Pages 1226-1233

  Garrity Park, M M ^a,c   Loftus Jr , E V ^b   Sandborn, W J ^b   Bryant, S C ^a   Smyrk, T C ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HLA DQ ANTIGEN; HLA DQ2 ANTIGEN; HLA DR ANTIGEN; HLA DR1 ANTIGEN; HLA DR15 ANTIGEN; HLA DR5 ANTIGEN; HLA DR7 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ADULT; AGED; ALLELE; ARTICLE; CANCER RISK; COLORECTAL CANCER; CONTROL GROUP; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE DURATION; DNA EXTRACTION; ETHNICITY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENE SILENCING; GENETIC PREDISPOSITION; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; ULCERATIVE COLITIS;

ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLORECTAL NEOPLASMS; FEMALE; GENE FREQUENCY; GENES, MHC CLASS II; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HLA-DQ ANTIGENS; HLA-DR ANTIGENS; HLA-DR1 ANTIGEN; HLA-DR7 ANTIGEN; HUMANS; IMMUNOHISTOCHEMISTRY; LOGISTIC MODELS; MALE; METHYLATION; MIDDLE AGED; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; RISK; TRANS-ACTIVATORS;

EID: 68849111629     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.166686     Document Type: Article

References (42)

1. Stokkers PC, Reitsma PH, Tytgat GN, et al. HLA-DR and -DQ phenotypes in inflammatory bowel disease: a meta-analysis. Gut 1999;45:395-401.
2. Marsh SGE, Parham P, Barber LD. The HLA facts book. London, San Diego: Academic Press, 1999.
3. Kübler K, Arndt PF, Wardelmann E, et al. HLA-class II haplotype associations with ovarian cancer. Int J Cancer 2006;119:2980-5.
4. Howell WM, Calder PC, Grimble RF. Gene polymorphisms, inflammatory diseases and cancer. Proc Nutr Soc 2002;61:447-56.
5. Ferguson LR, Shelling AN, Browning BL, et al. Genes, diet and inflammatory bowel disease. Mutat Res 2007;622:70-83.
6. Langholz E, Munkholm P, Davidsen M, et al. Course of ulcerative colitis: Analysis of changes in disease activity over years. Gastroenterology 1994;107:3-11.
7. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: Report of a working party of the 2005 Montreal World Congress of Gastroenterology. Can J Gasteroenterol 2005;19(Suppl A):5A-36A.
8. van Heel DA, Fisher SA, Kirby A, et al. Genome Scan Meta-Analysis Group of the IBD International Genetics Consortium. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet 2004;13:763-70.
9. Roussomoustakaki M, Satsangi J, Welsh K, et al. Genetic markers may predict disease behavior in patients with ulcerative colitis. Gastroenterology 1997;112:1845-53.
10. Brown SJ, Mayer L. The immune response in inflammatory bowel disease. Am J Gastroenterol 2007;102:2058-69.
11. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer: A population based study. N Engl J Med 1990;323:1228-33.
12. Itzkowitz SH, Yio X. Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation [review]. Am J Physiol Gastrointest Liver Physiol 2004;287:G7-17.
13. Wright KL, Ting JP. Epigenetic regulation of MHC-II and CIITA genes [review]. Trends Immunol 2006;27:405-12.
14. Radosevich M, Jager M, Ono SJ. Inhibition of MHC class II gene expression in uveal melanoma cells is due to methylation of the CIITA gene or an upstream activator. Exp Mol Pathol 2007;82:68-76.
15. van der Stoep N, Biesta P, Quinten E, et al. Lack of IFN-gamma-mediated induction of the class II transactivator (CIITA) through promoter methylation is predominantly found in developmental tumor cell lines. Int J Cancer 2002;97:501-7.
16. Morimoto Y, Toyota M, Satoh A, et al. Inactivation of class II transactivator by DNA methylation and histone deacetylation associated with absence of HLA-DR induction by interferon-gamma in haematopoietic tumour cells. Br J Cancer 2004;90:844-52.
17. Sharpe JC, Abel PD, Gilbertson JA, et al. Modulated expression of human leucocyte antigen class I and class II determinants in hyperplastic and malignant human prostatic epithelium. Br J Urol 1994;74:609-16.
18. Drozina G, Kohoutek J, Jabrane-Ferrat N, et al. Expression of MHC II genes. Curr Top Microbiol Immunol 2005;290:147-70.
19. Kanaseki T, Ikeda H, Takamura Y, et al. Histone deacetylation, but not hypermethylation, modifies class II transactivator and MHC class II gene expression in squamous cell carcinomas. J Immunol 2003;170:4980-5.
20. Satoh A, Toyota M, Ikeda H, et al. Epigenetic inactivation of class II transactivator (CIITA) is associated with the absence of interferon-gamma-induced HLA-DR expression in colorectal and gastric cancer cells. Oncogene 2004;23:8876-86.
21. Garrity-Park MM, Loftus Jr EV, Bryant SC, et al. Tumor necrosis factor-alpha polymorphisms in ulcerative colitis-associated colorectal cancer. Am J Gastroenterol 2008;103:407-15.
22. Wu Y, Liu B, Lin W, et al. Human leukocyte antigen class II alleles and risk of cervical cancer in China. Hum Immunol 2007;68:192-200.
23. Mahmud SM, Robinson K, Richardson H, et al. HLA polymorphisms and cervical human Papillomavirus infection in a cohort of Montreal University students. J Infect Dis 2007;196:82-90.
24. Hirata I, Murano M, Ishiguro T, et al. HLA genotype and development of gastric cancer in patients with Helicobacter pylori infection. Hepatogastroenterology 2007;54:990-4.
25. Li Z, Chen D, Zhang C, et al. HLA polymorphisms are associated with Helicobacter pylori infected gastric cancer in a high risk population, China. Immunogenetics 2005;56:781-7.
26. Coussens LM, Werb Z. Inflammation and cancer [review]. Nature 2002;420:860-7.
27. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease [review]. Nature 2007;448:427-34.
28. Danese S, Fiocchi C. Etiopathogenesis of inflammatory bowel diseases [review]. World J Gastroenterol 2006;12:4807-12.
29. Kucharzik T, Maaser C, Lügering A, et al. Recent understanding of IBD pathogenesis: implications for future therapies [review]. Inflamm Bowel Dis 2006;12:1068-83.
30. Meira LB, Bugni JM, Green SL, et al. DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest 2008;118:2516-25.
31. Kundu JK, Surh YJ. Inflammation: gearing the journey to cancer [review]. Mutat Res 2008;659:15-30.
32. Mitchell SA, Grove J, Spurkland A, et al. Association of the tumour necrosis factor alpha 2308 but not the interleukin 10 2627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001;49:288-94.
33. Donaldson PT, Norris S. Evaluation of the role of MHC class II alleles, haplotypes and selected amino acid sequences in primary sclerosing cholangitis. Autoimmunity 2002;35:555-64.
34. Jordanova ES, Philippo K, Giphart MJ, et al. Mutations in the HLA class II genes leading to loss of expression of HLA-DR and HLA-DQ in diffuse large B-cell lymphoma. Immunogenetics 2003;55:203-9.
35. Løvig T, Andersen SN, Thorstensen L, et al. Strong HLA-DR expression in microsatellite stable carcinomas of the large bowel is associated with good prognosis. Br J Cancer 2002;87:756-62.
36. van den Elsen PJ, Holling TM, van der Stoep N, et al. DNA methylation and expression of major histocompatibility complex class I and class II transactivator genes in human developmental tumor cells and in T cell malignancies [review]. Clin Immunol 2003;109:46-52.
37. Onken JE, Greer PK, Calingaert B, et al. Bromelain treatment decreases secretion of pro-inflammatory cytokines and chemokines by colon biopsies in vitro. Clin Immunol 2008;126:345-52.
38. Hershberg RM, Framson PE, Cho DH, et al. Intestinal epithelial cells use two distinct pathways for HLA class II antigen processing. J Clin Invest 1997;100:204-15.
39. Radosevich M, Song Z, Gorga JC, et al. Epigenetic silencing of the CIITA gene and posttranscriptional regulation of class II MHC genes in ocular melanoma cells. Invest Ophthalmol Vis Sci 2004;45:3185-95.
40. Croce M, De Ambrosis A, Corrias MV, et al. Different levels of control prevent interferon-gamma-inducible HLA-class II expression in human neuroblastoma cells. Oncogene 2003;22:7848-57.
41. Masternak K, Barras E, Zufferey M, et al. A gene encoding a novel RFX-associated transactivator is mutated in the majority of MHC class II deficiency patients. Nat Genet 1998;20:273-7.
42. Tosi G, Jabrane-Ferrat N, Peterlin BM. Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters. EMBO J 2002;21:5467-76.